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Background: Although overall survival for non-small cell lung cancer (NSCLC) has increased, survival rate for
pathologically staged T2aN0M0 stage IB NSCLC remains low. Adjuvant chemotherapy is not a standard treatment
for stage IB NSCLC. Our purpose was to determine the efficacy of platinum-based adjuvant chemotherapy in stage
IB NSCLC.
Methods: We retrospectively reviewed the medical records of 119 stage IB patients who underwent lobectomy
and mediastinal lymph node dissection. Among these, 60 patients underwent platinum-based adjuvant
chemotherapy (adjuvant group) and 59 did not receive chemotherapy (observation group).
Results: Participants had a mean age of 62.12 ± 11.51 years and 73 (61.3%) were male. The median follow-up
period was 49.04 months. Mean age was higher in the observation group whereas patients in the adjuvant group
had larger tumors, more dissected lymph nodes, and better performance status. The 5-year overall survival was
64.7% in the observation group and 88.2% in the adjuvant group (p = 0.010). The 5-year disease-free survival was
51.3% in the observation group and 74.0% in the adjuvant group (p = 0.011). In multivariate analysis, only
platinum-based adjuvant chemotherapy was a risk factor for overall survival [hazard ratio (HR) = 0.428, p = 0.049]
and disease-free survival (HR = 0.57, p = 0.043). In subset analysis, patients with a larger tumor (greater than 3.2 cm),
moderate to poor differentiation, and good performance status (Eastern Cooperative Oncology Group, 0) benefitted
from platinum-based adjuvant chemotherapy.
Conclusions: Platinum-based adjuvant chemotherapy for surgically treated stage IB NSCLC might offer better
survival than observation alone. A large-scale randomized clinical trial is needed to validate these findings.
Keywords: Lung cancer surgery, Adjuvant therapy, Statistics, Survival analysisBackground
Lung cancer is the leading cause of cancer deaths among
men and women worldwide [1]. Fewer than 20% of
patients diagnosed with lung cancer are candidates for
surgical resection. Among patients who are candidates for
surgical resection, the proportion with early stage non-
small cell lung cancer (NSCLC) has increased due to
surveillance programs and use of low-dose computed* Correspondence: kychu@yuhs.ac
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reproduction in any medium, provided the ortomography for screening [2]. The mainstay of treatment
for stage I NSCLC is complete surgical resection with me-
diastinal lymph node dissection. However, although the
overall survival for stage IA NSCLC has been reported to
be up to 73-90% with surgical treatment only [3,4], the
overall survival for pathologically staged T2aN0M0 stage
IB NSCLC remains low, at approximately 60% [4]. This
modest and unsatisfactory result for node-negative
NSCLC has been a source of frustration, and the possible
use of adjuvant treatment after surgical resection for stage
IB NSCLC has recently attracted interest among thoracic
surgeons and oncologists.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cacy of platinum-based adjuvant chemotherapy after sur-
gical resection in stage II–IIIA lung cancer [5-7]. The
efficacy of platinum-based adjuvant chemotherapy in stage
IB NSCLC also has been studied in a clinical trial [8] but
the final results did not demonstrate clear benefits of adju-
vant chemotherapy. Adjuvant chemotherapy is not cur-
rently a standard treatment for stage IB NSCLC and its
role in stage IB disease remains controversial. Recent
National Comprehensive Cancer Network (NCCN) guide-
lines recommend adjuvant chemotherapy with low-level
evidence (category 2B) in patients with stage IB NSCLC
and risk factors for poor survival. In our institution we
have performed adjuvant chemotherapy if patients with
risk factors such as poor differentiation, lymphovascular
invasion and pleural invasion, and patients were consid-
ered able to tolerate platinum-based adjuvant chemo-
therapy under the patient’s agreement on the adjuvant
therapy. Therefore, our experience provides an opportun-
ity to retrospectively evaluate the efficacy of platinum-
based adjuvant chemotherapy in stage IB NSCLC patients
who underwent complete surgical resection and systemic
mediastinal lymph node dissection.
Methods
Patients
This retrospective study was approved by the institutional
review board of the hospital (IRB No. 4-2012-0931). We
enrolled 119 patients who were confirmed to have
pathologic T2aN0 stage IB NSCLC after lobectomy and
complete lymph node dissection between January 2000
and December 2009. All patients underwent R0 resection
without neoadjuvant therapy and none received adjuvant
radiotherapy. We retrospectively reviewed the medical
records and pathologic data of these patients.
Chest computed tomography (CT), whole-body bone
scan, brain magnetic resonance imaging, bronchoscopy,
and pulmonary function testing were performed preopera-
tively in all patients. Positron emission tomography (PET)
was performed from approximately 2005 onwards. Postop-
eratively, we examined patients at 3-month intervals for the
first 2 years and at 6-month intervals thereafter on an out-
patient basis. The follow-up continued for at least 5 years.
The follow-up evaluation included physical examination,
chest radiography, and blood tests. Chest CT was obtained
at 6-month intervals, and positron emission tomography
scans were obtained annually to detect recurrences. If pa-
tients had any symptoms or signs of recurrence additional
imaging studies were performed regardless of the follow-up
schedule. Comorbidities were defined when patients had
preoperatively diagnosed cardiovascular disease (hyperten-
sion, coronary artery obstructive disease and arrhythmia),
cerebrovascular disease, pulmonary disease (tuberculosis,
chronic obstructive pulmonary disease and asthma) anddiabetes mellitus. Performance status was recorded accor-
ding to the Eastern Cooperative Oncology Group (ECOG)
performance scale [9]. Local recurrences were defined as
those occurring on resection margins, such as bronchial
stumps or stapler lines. Regional recurrences were defined
as those occurring in the hilar or mediastinal lymph nodes,
pleural cavity, and ipsilateral lung. Distant recurrences were
defined as those occurring in the contralateral lung, brain,
liver, adrenal glands, bone, and other locations.
Histopathologic reviews
Pathologic stages were diagnosed based on the Tumor,
Node, Metastasis (TNM) Classification of the International
Union Against Cancer, seventh edition [4]. All patients
were reclassified based on Seventh edition of the TNM
classification was published in 2007. The pathologic fea-
tures recorded included the following: tumor cell type,
degree of differentiation, tumor size by gross surgical spe-
cimen, lymphovascular invasion, and pleural invasion.
When cancer cells were observed in the intratumoral
lumen (i.e., vessels or lymphatics), the specimen was con-
sidered positive for lymphovascular invasion. Because
precise differentiation between vascular and lymphatic in-
vasion is difficult, we combined both into lymphovascular
invasion. When tumors abutted the visceral pleura or
when pleura were puckered, elastic-van-Gieson staining
was performed. Pleural invasion was classified according
to the following previously described criteria [10]: pl0,
tumor with no pleural involvement beyond its elastic layer;
pl1, tumor that extended beyond the elastic layer of the
visceral pleura but was not exposed on the pleural surface;
pl2, tumor that was exposed on the pleural surface but did
not involve the adjacent anatomic structures; and pl3,
tumor that involved adjacent anatomic structures.
Adjuvant chemotherapy
The adjuvant chemotherapy was performed if patients
with risk factors such as poor differentiation, lympho-
vascular invasion and pleural invasion, and patients were
considered able to tolerate platinum-based adjuvant che-
motherapy under the patient’s agreement. Platinum-based
adjuvant chemotherapy was started within 4 to 8 weeks
after surgical resection. Among the 60 patients who
received adjuvant chemotherapy, four cycles of cisplatin
(80 mg/m2) with paclitaxel or vinorelbine chemotherapy
were performed in 30 (50%) patients and four cycles of
carboplatin (an area under the curve dose of 6 mg/mL per
minute over 60 minutes) with paclitaxel or vinorelbine
were performed in the remaining 30 (50%). Among the 60
patients who underwent adjuvant chemotherapy, there
was no mortality related to chemotherapy. Seven (11.7%)
patients suffered from complications related to chemo-
therapy (pneumonia 3, nausea and vomiting 4) and they
could not complete the planned chemotherapy. Fifty three
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about dose reduction or dose delay were made by the
treating medical oncologist at the time of the scheduled
dose using objective criteria (white cell count, absolute
neutrophil count, serum creatinine, gastrointestinal symp-
toms, and neurologic symptoms) and subjective criteria
(performance status) [11].
Statistical analysis
Statistical analysis was performed using STATA 11
software (Stata Corp., Stata Statistical Software, Release 11
(2005, College Station. TX). Groups were compared using
the chi-square test or Fisher’s exact test for categorical
variables and t-test for continuous variables. Overall sur-
vival was calculated from the date of operation to the date
of death from any cause or the last follow-up. Disease-free
survival was calculated from the date of operation to the
date of the first recurrence or last follow-up. Other second
primary malignancies were not included as an event of
disease-free survival. The Kaplan-Meier method and log-Table 1 General characteristics of patients
No adjuvant therapy (n = 59)
Age (years) 64.14 ± 12.75
Male 36 (61.0%)
FEV1 (liters) 90.10 ± 25.99
Comorbidity 38 (64.4%)
Type of operation
Lobectomy 54 (91.5%)
Pneumonectomy 5 (8.5%)
Dissected lymph nodes 22.88 ± 9.21
Tumor size (mm) 28.35 ± 9.74
Pathology
Adenocarcinoma 27 (45.8%)
Squamous cell carcinoma 18 (30.5%)
Others 14 (23.7%)
Differentiation
Well 17 (28.8%)
Moderate to poor 37 (62.7%)
Not defined 5 (8.5%)
Lymphovascular invasion 8 (13.6%)
Pleural invasion
pl0 34 (57.6%)
pl1 15 (25.4%)
pl2 10 (16.9%)
Performance status (ECOG)
0 36 (61.0%)
1 20 (33.9%)
2 3 (5.1%)rank test were used to perform univariate survival analysis
and the Cox proportional hazard model was used to
identify independent prognostic factors. The parameters
were included in the Cox proportional hazard model if the
p-value was less than 0.2 on the log-rank test. The criter-
ion for significance was p less than 0.05 and all p values
were derived from two-tailed tests. All statistical analysis
was reviewed and verified by a statistician.
Results
General characteristics and pathologic results
Among the 119 patients, there were 73 male (61.3%) and
46 female patients (38.7%) with a mean age of 62.12 ± 11.51
years. The median follow-up period was 49.04 months
(range, 0.3-144.84 months). The mean and median tumor
size were 3.11 ± 1.01 cm and 3.2 cm (range, 0.8-4.8 cm),
respectively. Sixty patients (50.4%) underwent platinum-
based adjuvant chemotherapy (adjuvant group) and 59
(49.6%) patients did not receive adjuvant therapy (observa-
tion group). The general characteristics and comparisonsPlatinum-based chemotherapy (n = 60) p value
59.80 ± 9.70 0.027
37 (61.7%) 0.546
97.91 ± 25.40 0.1
33 (55.0%) 0.352
0.489
56 (93.3%)
4 (6.7%)
28.08 ± 13.08 0.017
33.80 ± 9.82 0.003
0.295
36 (60.0%)
14 (23.3%)
10 (16.7%)
0.306
12 (20.0%)
39 (65.0%)
9 (15.0%)
11 (18.3%) 0.323
0.428
28 (46.7%)
17 (28.3%)
15 (25.0%)
0.004
52 (86.7%)
8 (13.3%)
0
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higher in the observation group than the adjuvant group
(64.14 ± 12.75 vs. 59.80 ± 9.70, p = 0.027), whereas tumor
size was smaller (28.35 ± 9.74 vs. 33.80 ± 9.82, p = 0.003)
and the numbers of dissected lymph nodes was lower
(22.88 ± 9.21 vs. 28.08 ± 13.08, p = 0.017). Performance
status was better in the adjuvant group.Patterns of recurrence and death during the follow-up
period
Recurrence was reported in 29 (24.4%) patients as follows:
local recurrence (n = 2, 6.9%; both bronchial stump);
regional recurrence (n = 11, 37.9%; 2 pleural mass, 2 medi-
astinal lymph node, and 7 ipsilateral lung); and distant re-
currences (n = 16, 55.2%; 6 contralateral lung, 5 brain, 1
liver, 1 abdominal lymph node, and 3 bone). In adjuvant
group, recurrences were reported in 12 (20%) patients; no
local recurrence, 6 regional recurrences and 6 distant
metastases. In observation group, 17 (28.8%) patients suf-
fered from recurrences; 2 local recurrences, 5 regional re-
currences and 6 distant metastases. The patterns of
recurrence according to adjuvant chemotherapy were not
different (Chi-square test, p = 0.317).
Thirty patients died during the follow-up period. Half
of patients (n = 15) were died of cancer-related death
after recurrence and half of patients were died of cancer
non-related death. Among the most frequent cause of
death was second primary cancer and pneumonia during
follow-up periods (3 patients respectively).Overall survival and recurrence-free survival according to
platinum-based adjuvant chemotherapy
According to the Kaplan survival model and log-rank test,
the 5-year overall survival was 75.6% for all patients. The
5-year overall survival was 64.7% in the observation group
and 88.2% in the adjuvant group (p = 0.01). The 5-yearFigure 1 Survival curves. A. Overall survival curves according to adjuvantdisease-free survival was 51.3% in the observation group
and 74.0% in the adjuvant group (p = 0.011; Figure 1).
Risk factors for overall survival and disease-free survival
In univariate analysis, age, ECOG, and platinum-based
adjuvant chemotherapy were risk factors for overall sur-
vival. In multivariate analysis, only platinum-based adju-
vant chemotherapy was a risk factor for overall survival
[hazard ratio (HR) = 0.428, 95% confidence interval (CI)
0.184-0.998, p = 0.049; Table 2]. Platinum-based adjuvant
chemotherapy was also a risk factor for disease-free sur-
vival when adjusting for age, performance status, and
differentiation in multivariate analysis (HR = 0.57, 95%
CI 0.263-0.978, p = 0.043; Table 3).
Subset survival analysis for tumor size, performance
status, and differentiation
Subset analysis was performed to identify groups of patients
who might benefit from platinum-based adjuvant chemo-
therapy. Platinum-based adjuvant chemotherapy was effect-
ive in patients with tumor size greater than or equal to 3.2
cm (median tumor size) (HR = 0.256, 95% CI 0.076-0.854)
but was not effective in patients with tumor size less than
3.2 cm (HR= 0.6, 95% CI 0.191-1.887). Adjuvant chemo-
therapy was also effective in patients with moderate to poor
differentiation (HR = 0.222, 95% CI 0.074-0.667) and in
patients with ECOG 0 (HR= 0.309, 95% CI 0.108-0.889).
There were no survival differences with platinum-based
chemotherapy according to the presence of pleural
invasion.
In patients with tumor size greater than 3.2 cm (n = 63),
the 5-year overall survival was 72.0% in the observation
group and 91.9% in the adjuvant group (p = 0.017,
Figure 2A). In patients with moderate to poor differ-
entiation (n = 76), 5-year overall survival was 52.7%
in the observation group and 89.7% in the adjuvant
group (p = 0.003, Figure 2B). In patients with ECOGtherapy. B. Disease-free survival curves according to adjuvant therapy.
Table 2 Risk factors for overall survival in stage IB NSCLC
Univariate analysis Multivariate analysis (Cox hazard model)
HR (95% CI) p value HR (95% CI) p value
Age 1.053 (1.015-1.094) 0.006 1.031 (0.995-1.069) 0.092
Sex (female vs. male) 0.571 (0.254-1.284) 0.175 0.689 (0.300-1.584) 0.381
ECOG 1 (vs. 0) 2.343 (1.128-4.864) 0.022 1.717 (0.804-3.668) 0.163
2 (vs. 0) 0 0.976 0 0.977
Pneumonectomy 1.389 (0.421-4.585) 0.590 … …
Tumor size 0.980 (0.947-1.015) 0.264 … …
Numbers of dissected lymph nodes 0.987 (0.956-1.018) 0.408 … …
Adenocarcinoma
(vs. non-adenocarcinoma)
0.898 (0.437-1.845) 0.769 … …
Differentiation (moderate to poor vs. well) 1.317 (0.638-2.944) 0.419 … …
Lymphovascular invasion 0.494 (0.115-2.110) 0.341 … …
Pleural invasion (pl2 and pl1 vs. pl0) 1.228 (0.524-2.875) 0.637 … …
Platinum based chemotherapy
(vs. no adjuvant therapy)
0.360 (0.159-0.813) 0.014 0.428 (0.184-0.998) 0.049
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observation group and 92.3% in the adjuvant group
(p = 0.022, Figure 2C).Discussion
This retrospective study showed that platinum-based ad-
juvant chemotherapy offered better overall and disease-
free survival in surgically treated stage IB NSCLC than
observation alone. In particular, subset analysis showed
that patients with greater tumor size, moderate to poor
differentiation, and good performance status (ECOG 0)
benefitted from platinum-based adjuvant chemotherapy.Table 3 Risk factors for disease-free survival in stage IB NSCL
Univariate analysis
HR (95% CI)
Age 1.032 (1.004-1.062)
Sex (female vs. male) 0.795 (0.427-1.480)
ECOG 1 (vs. 0) 1.679 (0.895-3.149)
2 (vs. 0) 0.802 (0.107-5.989)
Pneumonectomy 1.176 (0.421-3.290)
Tumor size 0.998 (0.970-1.027)
Numbers of dissected lymph nodes 0.984 (0.960-1.010)
Adenocarcinoma
(vs. non-adenocarcinoma)
1.220 (0.675-2.206)
Differentiation
(moderate to poor vs. well)
1.675 (0.874-3.211)
Lymphovascular invasion 0.827 (0.322-2.124)
Pleural invasion (pl2 and pl1 vs. pl0) 0.953 (0.458-1.983)
Platinum based chemotherapy
(vs. no adjuvant therapy)
0.454 (0.244-0.847)There have been several studies on adjuvant chemo-
therapy in stage IB NSCLC. Daily administration of the
oral agent uracil-tegafur (UFT) for 2 years was proven to
be an effective adjuvant treatment for stage I NSCLC. A
randomized phase III study of UFT in 978 Japanese pa-
tients with stage I adenocarcinoma that was reported in
2003 demonstrated an HR for survival of 0.71 (p = 0.04)
[12]. The HR for UFT in a meta-analysis of six trials involv-
ing a total of more than 2000 patients was 0.74 (p = 0.001)
[13]. The benefit of UFT was limited to those with tumor
size greater than or equal to 2 cm. However, in contrast
to the current study, UFT was used as prolonged daily
maintenance and, moreover, UFT is not commerciallyC
Multivariate analysis(Cox hazard model)
p value HR (95% CI) p value
0.028 1.022 (0.994-1.051) 0.132
0.470 … …
0.107 1.552 (0.802-3.002) 0.192
0.829 0.980 (0.113-8.464) 0.985
0.757 … …
0.897 … …
0.207 … …
0.509 … …
0.120 … …
0.692 … …
0.897 … …
0.013 0.507 (0.263-0.978) 0.043
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Figure 2 Survival curves for subset analysis. A. Overall survival according to adjuvant therapy in patients with tumor size greater than or
equal to 3.2 cm (n = 63). B. Overall survival according to the adjuvant therapy in patients with moderate to poor differentiation (n = 76). C. Overall
survival according to the adjuvant therapy in patients with good performance status (n = 88).
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intravenous platinum-based adjuvant chemotherapy, the
Cancer and Leukemia Group B (CALGB) trial 9633 was
the only randomized adjuvant trial that focused exclusively
on patients with stage IB disease. CALGB 9633 trials used
paclitaxel with carboplatin and initially planned to involve
500 patients diagnosed with stage IB NSCLC after surgical
resection. Accrual to CALGB 9633 was stopped early with
344 patients by the Data and Safety Monitoring Board after
a planned interim analysis demonstrated that overall sur-
vival had crossed a pre-specified stopping boundary for ef-
ficacy, with an HR for overall survival of 0.62 (90% CI
0.44-0.89; p < 0.014) [8]. However, the 2006 updated re-
sults were no longer statistically significant for overall sur-
vival (HR = 0.8, p = 0.1). A statistically significant survival
advantage was still observed at 2 and 3 years, but statistical
significance was lost by 5 years with wide CIs. There are
many possible explanations for the final negative results
reported with CALGB 9633, including an underpowered
study (slow accrual and smaller numbers of patientsthan expected), a true lack of benefit from adjuvant
therapy in patients with stage IB disease, or a true lack
of benefit from carboplatin- (as opposed to cisplatin)
based adjuvant chemotherapy [14].
Although the efficacy of platinum-based adjuvant
chemotherapy in stage IB NSCLC has not been proven,
because of the modest overall survival and high recur-
rence rate for stage IB disease we have recommended and
performed platinum-based adjuvant chemotherapy accor-
ding to the preference of the surgeon and physician if the
patient has risk factors for poor survival and is considered
able to tolerate treatment. Oral UFT has not been pre-
scribed recently in our institution due to its unavailability.
We showed that platinum-based adjuvant chemotherapy
offered better overall and disease-free survival in surgically
treated stage IB NSCLC. Our results are noteworthy in
some aspects compared with previous reports [8,15,16].
First, the latest (7th) edition of TNM staging in lung can-
cer changed the staging criteria for tumor size in T2a from
‘greater than 3.0 cm’ to ‘greater than 3.0 cm and less than
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the 6th edition of TNM stage in lung cancer and included
larger-sized tumors greater than 5 cm, and the range of
tumor size in the CALGB 9633 trial was from 0 to 14 cm
[8]. In a subset analysis, patients in CALGB 9633 with
tumors greater than or equal to 4 cm had an overall sur-
vival advantage with an HR of 0.66 (p = 0.04) whereas the
74 patients in each arm with tumors less than 4 cm did
not show a difference in survival based on treatment with
an HR of 1.02 (p = 0.51). Despite the exclusion of tumors
larger than 5 cm, we detected a benefit of platinum-based
chemotherapy in patients with a larger tumor size using
criteria based on the 7th edition of TNM stage (more than
3.2 cm). Thus, the benefit of adjuvant chemotherapy was
still valid for tumors smaller than 5 cm. Second, we found
a benefit of platinum-based chemotherapy according to
differentiation and performance status. To our knowledge,
previous studies did not perform subset analysis according
to these characteristics.
However, this study should be interpreted with caution
because of several limitations. First, this is not a ran-
domized prospective study. The patient’s baseline char-
acteristics are different between the two groups: the
adjuvant group showed poor pathologic risk factors for
recurrence and survival such as poor differentiation and
large tumor size whereas the observation group showed
poor baseline characteristics for survival such as old age
and poor performance status. We considered propensity
score matching for comparison but did not perform it
due to the small number of subjects after matching. This
could be considered a shortcoming of this retrospective
study. However, instead of propensity score matching,
we adjusted for possible risk factors for overall and
disease-free survival such as performance status, age,
and sex in multivariate analysis. Despite the poor risk
factors for survival and recurrence, the adjuvant group
showed better survival than the observation group. Sec-
ond, as the regimens of chemotherapy were not consist-
ent in the adjuvant group we could not definitely
conclude that platinum-based adjuvant chemotherapy
had a benefit in stage IB lung cancer. Third, the median
follow up periods 49 months are relatively short. How-
ever, in lung cancer patients, the recurrences usually
develop within 2 or 3 years after operation. We think
that median 49 months could reflect the event of recur-
rence sufficiently given that these early recurrences.
Nonetheless, data from this retrospective study warrant
a large-scale randomized prospective study of the effi-
cacy of adjuvant chemotherapy in stage IB NSCLC.
What characteristics should be considered in a future
randomized prospective trial? First, it must include
many more patients than were enrolled in CALGB 9633.
Pignon et al. performed meta-analysis of large adjuvant
trials for NSCLC conducted since 1995 (excludingCALGB 9633) [18]. Their stage IB subset analysis (1,371
patients) trended toward a benefit of adjuvant treatment
(HR, 0.92) but failed to reach statistical significance (95%
CI, 0.73-0.95). This meta-analysis implied that the benefit
of platinum agent-based adjuvant chemotherapy in stage
IB NSCLC, if it exists, is small and would require a pro-
hibitively large trial to be detected. It must be noted that
for an HR of 0.8 to be statistically significant, the trial
would have required more than 1,000 patients [14]. Since
collecting more than 1,000 patients in a single institution
is impossible, a multi-center study is required. Second, be-
cause of the heterogeneity of stage IB NSCLC, selecting
patients at higher risk rather than enrolling the entire
stage IB population is the proper strategy [19]. CALGB
9633 reported that patients with tumors greater than or
equal to 4 cm showed an overall survival advantage with
an HR of 0.66 (p = 0.04). Our study demonstrated that in
addition to tumor size, other factors such as differentiation
and performance status have to be considered. Poor
pathologic characteristics that were reported in previous
studies should also be considered as an indication for ad-
juvant chemotherapy in stage IB NSCLC, in particular
lymphovascular invasion or pleural invasion. Although
several studies showed poor survival in patients with
pleural invasion [10,20], no analyses have reported the ef-
fect of adjuvant chemotherapy in node-negative T2 tumors
according to visceral pleural invasion [21]. Furthermore,
applying genomics and proteomics approaches to charac-
terize early lung cancer and determine the risk of recur-
rence could be considered.
Conclusion
In conclusion, platinum-based adjuvant chemotherapy for
surgically treated stage IB NSCLC might offer better sur-
vival than observation alone. In subset analysis, patients
with larger tumors, moderate to poor differentiation, and
good performance status (ECOG 0) appeared to benefit
from platinum-based adjuvant chemotherapy. A large-
sized prospective randomized clinical trial is needed to
determine its true efficacy.
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